Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Ribociclib (Primary)
Indications Leiomyosarcoma; Liposarcoma
Focus Therapeutic Use

Most Recent Events

22 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
23 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2023.
03 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 May 2023.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight